HLB Life ScienceHLB생명과학
067630 · KOSDAQ · ₩067630 · HLB생명과학
₩3,295▲ ₩15 (0.46%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩46B | ₩102B | ₩98B | ₩100B | ₩53B |
| Cost of sales | ₩46B | ₩104B | ₩99B | ₩103B | ₩59B |
| Gross profit | −₩494M | −₩2.2B | −₩749M | −₩3B | −₩5.5B |
| Operating income | −₩22B | −₩25B | −₩25B | −₩20B | −₩18B |
| Net income | −₩100B | ₩6.2B | −₩5.9B | −₩54B | −₩49B |
| Net income to shareholders | −₩100B | ₩6.1B | −₩6B | −₩54B | −₩49B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩478B | ₩539B | ₩424B | ₩412B | ₩271B |
| Current assets | ₩69B | ₩155B | ₩147B | ₩161B | ₩157B |
| Cash and equivalents | ₩13B | ₩53B | ₩17B | ₩31B | ₩31B |
| Total liabilities | ₩180B | ₩140B | ₩192B | ₩176B | ₩24B |
| Current liabilities | ₩119B | ₩54B | ₩135B | ₩27B | ₩14B |
| Borrowings | ₩108B | ₩123B | ₩165B | ₩144B | ₩3.5B |
| Total equity | ₩298B | ₩399B | ₩231B | ₩236B | ₩247B |
| Shareholders' equity | ₩297B | ₩398B | ₩231B | ₩235B | ₩246B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩23B | −₩32B | −₩10B | −₩30B | −₩14B |
| Capital spending | ₩26B | ₩27B | ₩21B | ₩11B | ₩2.4B |
| Free cash flow | −₩49B | −₩59B | −₩31B | −₩40B | −₩16B |
Consolidated where available. Amounts in won.
Also known as: HLB Life Science / HLB생명과학 / 067630 / KRX:067630
Source: KRX statistical information